NEW YORK (GenomeWeb) – The US Food and Drug Administration has expanded the indication for Myriad Genetics’ BRACAnalysis CDx, allowing it to be used to identify advanced ovarian cancer patients who are eligible to receive AstraZeneca’s Lynparza (olaparib) as first-line maintenance therapy after responding to platinum-based chemotherapy.